Zevra Therapeutics Inc.

05/13/2024 | Press release | Distributed by Public on 05/13/2024 14:48

Submission of Matters to a Vote of Security Holders - Form 8-K

Item 5.07Submission of Matters to a Vote of Security Holders.
On May 13, 2024, Zevra Therapeutics, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), for the following purposes:
●
to elect three Class III directors to the Company's board of directors to hold office until the 2027 annual meeting of stockholders;
●
to ratify the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024;
●
to approve, on an advisory and non-binding basis, the compensation of the Company's named executive officers; and
● to approve amendments to the Company's Amended and Restated 2014 Equity Incentive Plan.
Of the 41,850,494 shares outstanding as of the March 22, 2024 record date, at least 31,194,215 shares, or 74.54%, were present or represented by proxy at the 2024 Annual Meeting.
At the 2024 Annual Meeting, each of Thomas D. Anderson, Neil F. McFarlane, and Alvin Shih, M.D. was elected as a director of the Company. Also at the 2024 Annual Meeting, the stockholders of the Company ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024, and approved, on an advisory and non-binding basis, the compensation of the Company's named executive officers. The stockholders of the Company did not approve the amendments to the Company's Amended and Restated 2014 Equity Incentive Plan.
Based on tabulation and validation by Computershare, Inc., the independent inspector of election for the 2024 Annual Meeting, the final voting results on each of the matters submitted to a vote of stockholders at the 2024 Annual Meeting were as follows:
1.
Election of Directors
For
Withheld
Broker Non-Votes
Thomas D. Anderson
15,266,761 6,062,268 9,865,186
Neil F. McFarlane 12,413,828 8,915,201 9,865,186
Alvin Shih, M.D.
16,592,152 4,736,877 9,865,186
For
Against
Abstentions
Broker Non-Votes
2.
Ratification of the appointment ofErnst & Young LLP as theindependent registered public accounting firm for the Company's fiscal year ending December 31, 2024.
22,543,306 7,352,086 1,298,823 -
For Against Abstentions Broker Non-Votes
3. Approval, on an advisory and non-binding basis, of the compensation of the Company's named executive officers. 11,167,215 9,888,153 273,661 9,865,186
For Against Abstentions Broker Non-Votes
4. Approval of amendments to the Company's Amended and Restated 2014 Equity Incentive Plan 4,143,728 16,964,060 221,241 9,865,186